Background & Objective: Hypofractionation has been used in curative setting\nin breast conservative surgery, but still no adequate information about its\napplication in the adjuvant setting after mastectomy in breast cancer patients.\nThe aim of this trial was to assess the efficacy and toxicity of hypofractionation\nradiotherapy (40 Gy in 15 fractions) in post mastectomy breast cancer\npatients and to compare these results with those of post mastectomy patients\ntreated retrospectively by conventional radiotherapy (50 Gy in 25 fractions)\nas regard overall survival (OS), disease free survival (DFS), locoregional disease\nfree survival (LDFS), and toxicities. Patients & Methods: One hundred\npost mastectomy breast cancer patients were included into this study, they\nwere divided into 2 groups, the 1st included 50 patients treated prospectively\nwith hypofractionated radiotherapy regimen (40 Gy in 15 fractions), and the\n2nd (control group) included 50 patients treated retrospectively with conventionally\nfractionated radiotherapy regimen (50 Gy in 25 fractions). Results:\nThe 2 year overall survival were 96% & 94% respectively (p = 0.7), while the\ndisease free survival were 91% & 89.8%, respectively (p = 0.9), and the LDFS\nwere 95.8% & 93.3%, respectively (p = 0.9), G1 acute dermatitis was observed\nin 22 (44%) & 25 (50%) patients in group I & II respectively, G2 in 8 (16%) &\n10 (20%) patients respectively, no G4 skin toxicity was detected. Radiation\npneumonitis was observed in 2 patients (4%) only in group II. Conclusion:\npost-mastectomy hypofractionated radiation therapy achieved comparable\nsurvival and toxicity to the conventionally fractionated radiotherapy with the\nadvantage of reducing overall treatment time, treatment burden & cost.
Loading....